Cold chain failures can destroy biologics and cell therapies. Learn how real-time monitoring, validated packaging, and lane qualification reduce risk and protect patients.
- The Biggest Early-Stage Clinical Supply Mistake? Building Too Much, Too Soon.
- Study Start-Up Is Where Clinical Supply Risk Is Actually Decided
- How Clinical Supply Is Shaping The Next Generation Of Cell And Gene Therapies
- Clinical Trial Operations, Investigational Product Management, And The Foundation For Effective Risk Management
- Building Trust In Clinical Supply Digital Transformation
- Why Clinical Supply Teams Need To Understand CDISC
- The Hidden Cost Of Poor Data In Global Supply Chains
- The Hidden Cost Of Convenience: Single-Use Supply Chain Vulnerabilities And Clinical Trial Continuity
ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
Clinical, Commercial Packaging: Delivering Next-Gen Therapies
See how strategic, agile, and sustainable packaging is transforming drug delivery into a key driver of speed, safety, and patient-centric innovation.
-
RTSM Reusability: What It Is, Why Most Systems Lack It, And Why It Matters
Explore why RTSM should be viewed as a system for managing change. Learn how platform-based reusability reduces UAT churn, preserves institutional memory, and stabilizes mid-study amendments.
-
Common RTSM/IRT AN Medication Pooling Questions Answered
Whether you’re planning a single trial or an entire program, medication pooling offers a pathway to cost-effective and sustainable clinical trial management.
-
Building Robust Clinical Supply Chains To Support Global Trials
Ensuring drugs reach patients at the right time and place is crucial. Review key areas to consider as you build a robust clinical supply chain that supports global trials effectively and efficiently.
-
Streamlining Clinical Supply With Advanced Automation
Clinical trials are the backbone of pharmaceutical advancements, but they come with their own set of challenges, particularly in data management and supply chain logistics.
-
IRT? RTSM? What's The Difference?
What are the components of Randomization and Trial Supply Management (RTSM) and the critical role of RTSM and Interactive Response Technology (IRT) in clinical trials?
-
Consolidating Clinical Supply Chain Operations With GxP Inventory
A Japan-based biotechnology company leveraged Signant SmartSignals® GxP Inventory, which improved visibility, reduced risks and costs, and optimized operations in this case study.
-
Building A Flexible, Challenge Resistant, Patient-Centric Clinical Supply Chain
Flexible solutions, like demand-led supply and direct-to-patient distribution, are helping sponsors address the growing list of challenges presented by today’s increasingly complex studies.
-
Bespoke RTSM Systems Empower Precision Medicine
Randomization & trial supply management (RTSM) are critical functions of clinical trial IRT systems, supporting patient randomization plus managing drug inventory, site resupply, and participant dispensation.
-
Ensure Seamless, Efficient Delivery Of Clinical Trial Materials Worldwide
Drug discovery companies, CROs, and CDMOs are under pressure to find supply management solutions that ensure delivery of clinical trial materials while navigating complex study designs and the regulatory landscape.
- The Biggest Early-Stage Clinical Supply Mistake? Building Too Much, Too Soon.
- How Clinical Supply Is Shaping The Next Generation Of Cell And Gene Therapies
- First Advisors In: Meet Clinical Supply Leader's Inaugural Board Members
- What Clinical Wishes Supply Did Better – And How To Close The Gap: Part 3 – Staying Aligned in a Moving System
CATALENT CORNER
| Insights from Catalent's Clinical Supply Experts |
SPONSORED CONTENT
Impact Of Supplier Choice On APAC Clinical Trial Execution
Learn about strategies Asia-Pacific has become an increasingly complex and congested destination for clinical trials as local and global sponsors alike flock to the region to take advantage of its many benefits, including access to large patient pools. Choosing the right clinical packaging and supply chain partner to support these studies is critical and can vary significantly based upon what countries are involved and the types of services required.